Board of Directors

Joel Ackerman

Joel Ackerman was appointed Chairman of the Board of Directors of the Company in January 2017. He was CEO and Director of the Company from 2010 to 2017. Prior to Champions, he spent 15 years at Warburg Pincus, a leading private equity investment firm, from 1993 to 2008. While at Warburg Pincus, he was a partner of the firm, a member of the executive management group and ran the healthcare services group. He invested in start-ups and early-stage companies as well as later-stage growth investments and management-led buyouts. For most of these companies, Mr. Ackerman served on the board of directors and worked closely with the respective management teams on strategy, financing, M&A and organizational development. Currently, Mr. Ackerman sits on the board of directors of Coventry Health Care, a publicly traded managed care company, and Kindred Healthcare, a publicly traded company that owns hospitals and nursing homes. He is also chairman of the board of One Acre Fund, a nonprofit microfinance organization in Western Kenya. He received a BA in physics from Columbia University and an MA in physics from Harvard University.

David Sidransky, MD

David Sidransky, MD was appointed Lead Director of the Company in January 2017. He was Chairman of the Board of Directors of the Company from 2007 to 2017. Dr. Sidransky is a renowned oncologist and research scientist named and profiled by TIME magazine in 2001 as one of the top physicians and scientists in America, recognized for his work with early detection of cancer. Since 1994, Dr. Sidransky has been the director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine and professor of oncology, otolaryngology, cellular & molecular medicine, urology, genetics, and pathology at John Hopkins University and Hospital.

During the past decade, in the field of oncology, Dr. Sidransky has been one of the world’s most highly cited researchers in clinic and medical journals, with over 300 peer-reviewed publications. He has contributed more than 40 cancer reviews and chapters. Dr. Sidransky is a founder of a number of biotechnology companies and holds numerous biotechnology patents. He has served as vice chairman of the board of directors, and was, until the merger with Eli Lilly, a director of ImClone Systems Inc., a global biopharmaceutical company committed to advancing oncology care. He is the chairman of Alfacell Corporation and serves on the board of directors of Xenomics. He is serving, and has served, on scientific advisory boards of MedImmune, Roche, Amgen and Veridex, LLC (a Johnson & Johnson diagnostic company), among others. Dr. Sidransky served as director (2005-2008) of the American Association for Cancer Research (AACR). He was the chairperson of AACR International Conferences (2006 and 2007) on Molecular Diagnostics in Cancer Therapeutic Development: Maximizing Opportunities for Personalized Treatment.

Dr. Sidransky is the recipient of a number of awards and honors, including the 1997 Sarstedt International Prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award Relating Smoking and Health by the American College of Chest Physicians, and the 2004 Richard and Hinda Rosenthal Memorial Award from the American Association for Cancer Research.

Daniel Mendelson

Daniel N. Mendelson has served as a Director of the Company since March 2013. Mr. Mendelson is Operating Partner at Welsh Carson, a private equity firm. He is also presently Advisor to Avalere Health, a healthcare advisory and analytics, that he Founded in 2000 and sold to Inovalon Holdings in 2015. The firm’s customer base includes Fortune 500 healthcare companies, provider organizations, medical foundations and government. Mr. Mendelson is also an Executive in Residence of the Fuqua School of Business at Duke University, and sits on the board of Centrexion, a private company focused on non-addictive alternatives to opioid therapies. From 1998 to 2000, Mr. Mendelson served as associate director for health at the Office of Management and Budget (OMB). Prior to joining OMB, Mr. Mendelson was senior vice president of The Lewin Group and director of the medical technology practice. He holds an undergraduate degree in economics from Oberlin College, and a MPP from the Kennedy School of Government at Harvard University.

Abba David Poliakoff

Abba David Poliakoff is a member of the law firm of Gordon, Feinblatt, Rothman, Hoffberger & Hollander, LLC, in Baltimore, Maryland, chairman of the firm’s Business Department, and a member of the firm’s Electronic Discovery Practice Group. Mr. Poliakoff received his JD degree, magna cum laude, in 1977 from the University of Baltimore Law School, where he was an editor of the University of Baltimore Law Review and associate editor of The University of Baltimore Law Forum. After law school, Mr. Poliakoff joined the staff of the U.S. Securities and Exchange Commission in Washington, D.C., where he became a senior attorney in the Division of Corporation Finance.

Mr. Poliakoff is currently a member of the Maryland State Bar Association’s Business Law Section and former chair of its Committee on Securities. Formerly, he was a member of the Business Regulations Article Review Committee of the Committee to Revise the Annotated Code of Maryland. He has been named on Chambers USA’s list of Leading Lawyers for Business since its inception in 2003. Mr. Poliakoff is a member of the board of directors of the Greater Baltimore Technology Council (GBTC) and chair of its Legislative Committee. He is a former chair of the Maryland Business & Technology Coalition, a member of the Tech Council of Maryland and a member of the MIT Enterprise Forum. Mr. Poliakoff is currently the chairman of the Maryland/Israel Development Center, a joint venture between the State of Israel and the state of Maryland collaborating through the Maryland Department of Business and Economic Development and the Israeli Ministry of Industry, Trade and Labor.

Scott Tobin

Scott R. Tobin has served as Director of the Company since June 2011. Mr. Tobin joined Battery Ventures, a venture capital firm, in 1997 where he has been a managing partner of various funds affiliated with the firm since May 2000. Prior to joining Battery, Mr. Tobin held positions at First Albany Corp. and at Future Vision, a software company that was sold to SoftKey International. Mr. Tobin has invested in and been active in the management of Battery’s investments in ActivePath, Akamai Technologies, Anobit Technologies, @stake (acquired by Symantec), Istra Research, ITA Software (acquired by Google), Kashya (acquired by EMC), The London International Financial Futures and Options Exchange (LIFFE; acquired by Euronext), MetroPCS, ProfitLogic (acquired by Oracle), Pursway, Sabre, The Tennis Channel, Ximian (acquired by Novell) and Zerto.